trial · primary record
Botensilimab
Early Rectal Cancer
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 16 |
| Primary completion | 2032-12-31 |
| Primary endpoint | Complete response (cCR plus nCR with pCR at resection) within 6 months from initiation of therapy or nCR with pathologic complete response (pCR) with TES |
| Registry ID | NCT07735624 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:46.205Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07735624
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.